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Abstract
Background: The treatment of AIDS remains a serious challenge owing to high genetic variation of Human 
Immunodeficiency Virus type 1 (HIV-1). The use of different antiretroviral drugs (ARV) is significantly limited by severe 
side-effects that further compromise the quality of life of the AIDS patient. In the present study, we have evaluated a 
liposome system for the delivery of nevirapine, a hydrophobic non-nucleoside reverse transcriptase inhibitor. 
Liposomes were prepared from egg phospholipids using thin film hydration. The parameters of the process were 
optimized to obtain spherical liposomes below 200 nm with a narrow polydispersity. The encapsulation efficiency of 
the liposomes was optimized at different ratios of egg phospholipid to cholesterol as well as drug to total lipid. The 
data demonstrate that encapsulation efficiency of 78.14% and 76.25% were obtained at egg phospholipid to 
cholesterol ratio of 9:1 and drug to lipid ratio of 1:5, respectively. We further observed that the size of the liposomes and 
the encapsulation efficiency of the drug increased concomitantly with the increasing ratio of drug and lipid and that 
maximum stability was observed at the physiological pH. Thermal analysis of the drug encapsulated liposomes 
indicated the formation of a homogenous drug-lipid system. The magnitude of drug release from the liposomes was 
examined under different experimental conditions including in phosphate buffered saline (PBS), Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum or in the presence of an external stimulus such as 
low frequency ultrasound. Within the first 20 minutes 40, 60 and 100% of the drug was released when placed in PBS, 
DMEM or when ultrasound was applied, respectively. We propose that nevirapine-loaded liposomal formulations 
reported here could improve targeted delivery of the anti-retroviral drugs to select compartments and cells and 
alleviate systemic toxic side effects as a consequence.
Introduction
According to the World Health Organization, more than
40 million people have been presently infected with
Human Immunodeficiency Virus type 1 (HIV-1) globally.
Highly Active Antiretroviral Therapy (HAART), which
consists of a combination of a minimum of three antiret-
roviral (ARV) drugs, is the primary treatment currently
available for efficient management of AIDS [1,2]. The
various types of ARVs that are used in HAART could be
categorized into nucleoside reverse transcriptase inhibi-
tors (NRTIs), nucleotide reverse transcriptase inhibitors
(nRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), viral fusion inhibi-
tors, integrase inhibitors, maturation inhibitors and fixed
dose combination [1]. These drugs have a potential to
manage the chronic infection but not to treat the disease
[3]. The bioavailability of many of the ARV drugs is con-
siderably low and erratic due to the substantial first pass
metabolism and degradation in the gastrointestinal tract.
Given the short half-life of the drugs, frequent adminis-
tration of the drugs is required at relatively higher doses,
often leading to low patient compliance [4]. If adherence
falls below 95% level, the therapeutic effectiveness is
reduced below 50% [3]. Immunologically privileged com-
partments of the body including the central nervous sys-
tem, lymphatic system and the macrophages are
characteristically inaccessible to a majority of the ARV
drugs thus serving as viral reservoirs [5]. The inability to
maintain therapeutic concentration of the drugs for lon-
ger durations significantly contributes to multidrug-resis-
tance [6]. Furthermore, the prolonged use of ARVs
frequently leads to toxic side effects resulting in the dete-
rioration in the quality of life and incompliance to ther-
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apy [7]. Nevirapine is a hydrophobic NNRTI that non-
competitively binds to an allosteric non-substrate binding
site of the reverse transcriptase (RT) [8,9]. Nevirapine,
the first ARV member of non-nucleoside reverse tran-
scriptase inhibitor approved by the Food and Drug
Administration (FDA) for HIV and an important compo-
nent of HAART, is typically the primary choice for effi-
cient viral suppression. Unfortunately, the use of
nevirapine is frequently accompanied by severe side-
effects that include CNS toxicity, hepatotoxicity, insom-
nia, confusion, memory loss, depression, rash, nausea,
dizziness, Stevens-Johnson syndrome, toxic epidermal
necrolysis and hyperlipidemia [8-16]. It has also been
reported to cause severe liver toxicity within first six
weeks of treatment. The US FDA has issued a 'black box
label' on nevirapine due to its hepatotoxicity [14]. The use
of nevirapine has been restricted except in cases where
the benefit to the patient exceeds the risk. Therefore the
development of a delivery system for sustained and tar-
geted release of nevirapine can enhance the clinical
potential of this antiretroviral drug. Nevirapine also
reduces the level of certain co-administered drugs includ-
ing the antiretroviral drugs indinavir, lopinavir, efavirenz.
In order to prevent such undesired interactions, encapsu-
lation of nevirapine in a carrier is expected to be benefi-
cial. Given the paradoxical context, there exists a need to
develop targeted and sustained drug delivery systems to
reduce the frequency of dose administration on the one
hand and to maintain therapeutic concentration of the
drug for extended periods with enhanced efficacy on the
other hand which could also improve patient compliance.
The liposomal carrier system is expected to reduce the
side-effects due to sustained release of the drug and pro-
vide sufficient cellular uptake due to its nano-dimensions.
A range of novel strategies are currently being devel-
oped for efficient delivery of ARV drugs. Efficient deliv-
ery could be achieved by encapsulating the drug or by
attaching it with a carrier system [17-19]. Several delivery
systems have been reported for the delivery of ARV drugs
including bioadhesive coated matrix tablets [20,21],
ceramic implants [22], liposomes [23-26], solid colloidal
nanoparticles [27-30], dendrimers [31], micelles & micro-
emulsion [32], nanopowders [33] and suspensions [34].
Liposomes are nanocarriers that range from 25 nm to
several microns and are prepared using combinations of
natural or synthetic phospholipids and cholesterol [35].
Liposomes incorporate hydrophilic drugs through an
aqueous core or entrap hydrophobic drugs using phos-
pholipid bilayer(s) which surrounds the aqueous core.
Since some of the cells of the immune system like the
macrophages and microglial cells could serve as the viral
reservoirs, liposomes could potentially target ARV drugs
into the infected cells thereby improving the efficacy and
reducing the side-effects [36]. The primary aim of the
present study was to develop and characterize nevirap-
ine-loaded liposomes and to investigate the effect of vari-
ous parameters on the size and the encapsulation
efficiency of the liposomes including the lipid composi-
tion, drug-lipid ratio and pH of the medium. The release
kinetics of nevirapine in solutions at varying pH and cul-
ture medium in the presence and absence of an external
stimulus were determined.
Materials and methods
Materials
Methanol, phosphotungstic acid, sodium chloride,
sodium dihydrogen phosphate, disodium hydrogen phos-
phate, sucrose, chloroform, hydrochloric acid were pur-
chased from Merck Chemicals, India and used as such
without further purification. Egg phosphatidyl choline
(EPC) was procured from Sigma-Aldrich, USA. Nevirap-
ine was a kind gift from Bohringer Ingelheim, Germany.
Preparation of Liposomes
Egg phospholipids were extracted from yellow yolk by the
modified Singleton-Gray method [37]. The lipid compo-
sition of egg phospholipids have been identified using the
GC-MS (Agilent technologies, Model 7890 A series, GC
with 5975C Mass spectrometer). The results indicate that
the egg phospholipid contains three different lipid con-
stituents such as PLPC (89%), POPE (3%) and cholesterol
(6%). Liposomes were prepared using the thin film hydra-
tion technique. Briefly, 100 mg/mL of phospholipids in
chloroform taken in a clean moisture-free container was
purged with nitrogen gas to remove the solvent. Five mL
of phosphate buffered saline (PBS), pH 7.4, were added to
the container and the mixture was warmed at 60°C for 30
minutes. The solution was then extruded through poly-
carbonate membranes of 200 nm pore size using an
extruder (Liposofast Basic, Avestin, Canada) for ten
cycles to obtain extruded liposomes. The liposomes were
lyophilized (Virtis Model Benchtop K, USA) and stored at
-20 °C in air-tight vials.
Drug Loading
Nevirapine loaded liposomes were prepared dissolving
eight different ratios of drug to phospholipids (1:1, 1:2,
1:3, 1:4, 1:5, 1:6, 1:7 and 1:10). Briefly, a total amount of
lipid consisting of 10 mg of phospholipids in chloroform
and different quantities of nevirapine was dissolved in
chloroform and the liposomes were prepared as
explained above.
Morphological Characterization
The morphology of the liposomes was determined using
a scanning electron microscope (JEOL 6701F, Japan). The
samples were placed over a carbon paste coated stub and
sputter coated with a thin layer of platinum prior to view-
ing. For negative staining, 2% (w/v) phosphotungstic acidRamana et al. Journal of Biomedical Science 2010, 17:57
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was added to the liposome samples and incubated at
room temperature for 24 hours. This sample was freeze
dried and imaged using scanning electron microscope.
The transmission electron micrographs of the liposomes
were obtained using JEM 1011, JEOL, Japan. The lyo-
philized liposome sample was dispersed in 0.5 mL PBS.
To 50 μL of this dispersion, an equal volume of double
distilled water was added and placed on a carbon coated
grid. The excess water was absorbed using a filter paper
and uranyl acetate stain was added. The grid was then
washed with water to remove excess uranyl acetate and
then dried before it was loaded in the specimen chamber.
The percentage aqueous volume of liposome was calcu-
lated using the formula
Particle Size Analysis
The particle size of the liposomes and drug loaded lipo-
somes were determined using laser diffraction method
(Microtrac Blue wave, Japan) at room temperature. Five
mL of the sample was introduced into the particle size
analyzer at 50% flow rate to measure the mean size and
size distribution of liposomes and drug loaded liposomes.
Thermal Analysis
Two mg of liposome samples were loaded in aluminum
pans along with the standard reference aluminum in the
differential scanning calorimeter (Q20, TA Instruments,
USA). The DSC was recorded between 10°C and 90°C at a
scan rate of 10°C/min for three cycles.
Determination of Encapsulation Efficiency
The extruded liposomal samples were centrifuged at
3,000 rpm (Eppendorf 3340R, Germany) at 4°C to pellet-
ize the unencapsulated drug. The supernatant was centri-
fuged at 10,000 rpm to pelletize the drug loaded
liposomes [38]. The pellet was then treated with 1% Tri-
ton X-100 (Sigma-Aldrich, USA) to disrupt the lipo-
somes. The sample was centrifuged at 3000 rpm again to
pelletize the drug alone. The supernatant was removed
and the pellet was resuspended and the concentration of
t h e  e n c a p s u l a t e d  d ru g  w a s  m e a s u r e d  as  a b s o r b a n c e  a t
284 nm using UV-visible spectrophotometer (Lambda 25,
Perkin Elmer, USA). The absorbance was converted into
drug concentration using a standard curve.
The encapsulation efficiency was calculated as:
All experiments were carried out in triplicate.
Release Kinetics
Dialysis bags (Dialysis membrane 110, Hi Media, India)
were immersed in water for one hour to remove the pre-
servatives followed by rinsing in phosphate buffered
saline (PBS) solution. The drug encapsulated liposomes
were placed in PBS and loaded in the dialysis bag. The
bag was sealed at both the ends and immersed in 4 mL of
PBS with 10% methanol [39]. The release of the drug was
evaluated at three different pH values (1.2, 7.4 and 9.0). A
pH of 1.2 was maintained using 0.1 M HCl -KCl buffer
while pH 9.0 was maintained using 0.1 M phosphate buf-
fer. In order to evaluate the influence of proteins on the
release of nevirapine from the liposomes, Dulbecco's
Modified Eagle's Medium (DMEM, HiMedia, India) sup-
plemented with 10% fetal bovine serum (FBS, HiMedia,
India) was used as the release medium. The effect of
ultrasound on the release profile of the drug from the
liposomes was studied in PBS (pH 7.4) as the release
medium. Low frequency ultrasound (20 KHz) was
applied using a bath sonicator (UT 002, ABM, India) for
the entire duration of the release study. For all drug
release studies, 4 ml of the release medium was with-
drawn for analysis at different time intervals (0-25 hours)
and replaced with 4 mL of fresh medium. The amount of
drug released was measured as absorbance using a UV-
visible spectrophotometer (Lambda 25, Perkin Elmer,
USA). The absorbance was converted into percentage
release using a standard curve.
Statistics
Analysis of Variance (Two-way Anova) was performed to
determine the statistical significance (p < 0.05) for per-
centage encapsulation (n = 3) and percentage of drug
release (n = 3) under various experimental conditions. If
statistically significant, a post-hoc Tukey test was per-
formed to determine which means were different from
the others.
Results & Discussion
The mean particle size of the liposomes prepared using
thin film hydration technique was 157 nm. The scanning
electron micrograph of the lyophilized liposome indicates
a spherical morphology and size in the nanodimensions
(Figure 1A). Figure 1B presents the transmission electron
micrograph of the liposomes clearly demarcating an
aqueous phase in the centre of the liposome. The average
aqueous volume of the liposomes determined from the
various transmission electron micrographs is 15.54%.
This small aqueous volume is likely due to the small vesi-
cle sizes obtained in which considerable volume is occu-
pied by the membrane [40].
The colloidal stability of the liposomes was investigated
at three different pH conditions, 1.2, 7.4 and 9.0 at the
end of incubation for defined time points (Figure 2). We
PercentageAqueousVolume
AqueousVolume
TotalVolumeofLiposome
=× ×100
EncapsulationEfficiency
DrugEncapsulated
TotalDrug
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observed that the size of the liposomes was significantly
influenced by the pH of the medium. The size of the lipo-
somes changed significantly at both acidic (1.2) and basic
pH (9.0) when compared to the neutral pH (7.4). For the
first two hours, the liposome size increased regardless of
the pH differences (Figure 2, panels D, E & F). This may
be attributed to the secondary particle growth due to ves-
icle fusion or Ostwald ripening which is expected to be
promoted by small vesicles because of their high mem-
brane curvature [41,42]. At later time points, the size of
the liposomes at acidic and alkaline pH showed a signifi-
cant decrease as compared to pH 7.4 (Figure 2, panels G,
H & I). This may be attributed to the competitive hydro-
lysis of the phospholipids that may occur spontaneously
in the media resulting in the destruction of the liposomal
architecture leading to size reduction. Further, increased
accumulation of dipoles at the membrane interface may
also lead to reduced aggregation [43]. However, no such
size reduction was observed at pH 7.4 instead a gradual
increase in the liposomal size towards the micron range
was noticed due to a major contribution from Ostwald
ripening (Figure 2). With increasing salt concentration
the liposomes start to aggregate. However, as hydrolysis
starts dominating, the charged phosphate head groups
are hydrolyzed leading to a reduction of charge and hence
an associated reduction in the micron sized liposomes
[44].
After the initial aggregation, two distinct size groups of
liposomes - nano and micro size liposomes were formed
at both acidic (Figure 2G) and alkaline pH conditions
(Figure 2I). As a function of time the size of the particles
decreased and larger fraction of the liposomes were seen
in the nanoscale range at both acidic (Figure 2J) and basic
(Figure 2L) pH conditions.
Since lipid composition could have significant impact
on liposome size, stability, drug loading and delivery
functions, we examined the physical properties of the
liposomes synthesized at varying ratios of egg phospho-
lipids and cholesterol. The encapsulation efficiency of
liposomes constituted from varying concentrations of
phospholipid and cholesterol for nevirapine loading was
compared (Figure 3). The encapsulation efficiency of the
liposomes was significantly influenced by the presence of
cholesterol and its drug to lipid ratio. Liposomes consist-
ing of cholesterol (at 9:1 ratio) showed significantly
increased encapsulation efficiency for nevirapine as com-
pared to the particles without cholesterol (at 10:0 ratio, p
< 0.05). The enhanced loading capacity of the liposomes
may be attributed to a combined effect of increased
hydrophobicity and or increased liposome size due to
cholesterol incorporation [45]. Importantly, further
increase in the cholesterol content did not enhance drug
loading capacity of the liposomes instead, in fact reduced
the encapsulation efficiency. High levels of cholesterol
have been reported to interfere with the close packing of
lipids in the vesicles by contributing to an increase in
membrane fluidity which results in an increased distribu-
tion of aqueous phase within the liposomal vesicle
thereby reducing the encapsulation of the hydrophobic
nevirapine [46]. The encapsulation efficiency of the lipo-
somes was not significantly affected by the substitution of
egg phospholipids with synthetic egg phosphatidyl cho-
line probably because phosphatidyl choline is the major
constituent in egg phospholipid mixture. We measured
the effect of the drug-lipid ratio on liposome diameter
and encapsulation efficiency. The results demonstrate
that the size of the drug loaded liposomes decreased sig-
nificantly from 188 ± 1.2 nm to 73 ± 7.8 nm when the
Figure 1 SEM and TEM micrographs of the lyophilized liposomes. 
(A) The sample was imaged s performed at a magnification of 43,000. 
Inset shows the magnified image of spherical liposome (B) TEM micro-
graphs of liposome at a magnification of 60,000.Ramana et al. Journal of Biomedical Science 2010, 17:57
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Figure 2 Effect of pH on colloidal stability of liposome.
Figure 3 Effect of Cholesterol on the encapsulation efficiency of 
nevirapine. Statistical data infers that each group is significantly 
different (p < 0.05).
Figure 4 Correlation between the mean particle size (white circle) 
and percent encapsulation efficiency (Black square) at various 
drug-lipid ratios.Ramana et al. Journal of Biomedical Science 2010, 17:57
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drug-lipid ratio was decreased from 1:10 to 1:1 (Figure 4).
A reduction in the liposome size is expected to shrink the
aqueous volume of the liposome resulting in lesser
encapsulation of a lipophilic drug like nevirapine [47].
Furthermore, significant increase in the amount of drug
loading was observed with increasing drug-lipid ratio up
to 1:5 (p < 0.05)but not beyond these ratio (Figure 4).
The encapsulation of nevirapine in the liposomes was
confirmed by DSC measurements (Figure 5). The endo-
thermic phase transition temperature of the plain lipo-
somes and nevirapine loaded liposomes was found to be
52.80°C and 37.27°C, respectively (Figure 5). A negative
shift in the transition temperature indicates a strong
hydrophobic interaction between nevirapine and the
phospholipids forming the liposome. The absence of flat-
tened peaks indicates the homogeneity in the lipids form-
ing the liposome [48].
The drug release profile of nevirapine from the lipo-
somes was studied at three different pH conditions (1.2,
7.4 and 9.0) and in a standard culture medium supple-
mented with serum. As shown in (Figure 6), during the
initial half an hour, a burst release of nevirapine was
observed under all the experimental conditions. Approxi-
mately, 53.98 ± 1.85%, 36.39 ± 3.68% and 37.10 ± 1.65% of
the drug was released at the pH values of 1.2, 7.4 and 9.0,
respectively . The magnitude of drug released at pH 1.2
was significantly higher as compared to pH 7.4 and 9.0 at
all the time points (p < 0.05) (Figure 6). However, the
amount of drug released at pH 7.4 and 9.0 was compara-
ble to each other throughout the study period (p > 0.05)
(Figure 6). At pH 1.2, nearly 90% of nevirapine was
released within 8 hours (90.17 ± 3.13%). However, to
release an equivalent amount, 15 and 12 hours will be
required at pH 7.4 (87.07 ± 4.08%) and 9.0 (86.37 ±
3.86%), respectively. The faster drug release in the acidic
and basic media may be attributed to the accelerated
hydrolysis of the carrier [49].
Drug release from liposomes measured in vitro in buf-
fers and solutions may or may not be extrapolated to in
vivo conditions given the highly complex composition of
the physiological fluids including the presence of pro-
teins. Ultrasound-triggered delivery systems are gaining
popularity for their non-invasive nature and controlled
release ability [50]. To investigate whether the synthetic
Figure 5 SC thermograms of plain (filled line) and nevirapine-loaded (dashed line) liposomes.Ramana et al. Journal of Biomedical Science 2010, 17:57
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liposomes demonstrate echogenic effect, we compared
nevirapine release profiles from drug-loaded liposomes
under different experimental conditions, in PBS or
DMEM with or without low frequency ultrasound treat-
ment (Figure 7). It was observed that 87.07 ± 4.08% of the
drug was released in 900 minutes when placed in PBS as
compared to 94.82 ± 2.32% in 180 minutes for DMEM
and 96.86 ± 1.62% in 70 minutes while using ultrasound
(Figure 7). In the first 60 minutes the percentage release
of nevirapine in PBS, DMEM and ultrasound triggered
release was found to be 51.92 ± 2.60%, 74.51 ± 3.74% and
91.51 ± 2.66%, respectively suggesting an initial burst
release (Figure 7). The faster release in DMEM when
compared to PBS may be attributed to the presence of
several host derived factors including albumin protein in
the cell culture medium, which could displace the phos-
pholipids in the liposomes resulting in enhanced fluidity
thereby causing a fast release of the drug [50]. Similarly
most of the drug was released within 60 minutes when
ultrasound was applied (Figure 7). This may be attributed
to the development of highly localized pressure spots that
disrupt the drug-lipid interactions and lipid-lipid interac-
tions resulting in the observed release pattern.
We evaluated the influence of medium and cholesterol
on the ultrasound triggered release profiles from nevirap-
ine loaded liposomes. We observed that the combined
effect of medium and ultrasound accelerate the release of
n evi r a p i n e  f r o m  t h e  l i po s o m e s.  M o r e  t h a n  9 0 %  o f  t h e
drug was released within 20 minutes (Figure 8). The
release follows a first order kinetics and the fast release
may be attributed to the combined fluidization effect of
proteins in the medium and ultrasound. Furthermore,
when cholesterol was incorporated into the liposomes
(9:1 ratio), regardless of the presence or absence of
DMEM, the pattern of drug release was comparable in
response to ultrasound treatment (Figures 7 and 8). This
may be due to the additional rigidity conferred by choles-
terol to the liposome thus preventing the displacement of
phospholipids by the proteins found in the medium [51].
Figure 6 Release profile of nevirapine from liposomes at various pH containing phospholipid to cholesterol in ratio 9:1 (* < 0.05).Ramana et al. Journal of Biomedical Science 2010, 17:57
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Conclusions
Liposomes of uniform diameters were prepared using
thin film hydration and extrusion technique and a hydro-
phobic non-nucleoside reverse transcriptase inhibitor,
nevirapine, was successfully encapsulated in the lipo-
somes. The best encapsulation was observed at an egg
phosholipid to cholesterol ratio of 9:1 which also showed
a prolonged release of nevirapine up to 1320 minutes at
physiological pH. Presence of proteins in the medium and
external stimuli like low frequency ultrasound was found
to enhance the rate of drug release. The use of ultrasound
leading to higher magnitude of drug release thus points to
a potentially novel approach towards anti-retroviral ther-
apy. Presence of cholesterol in the liposomes offers stabil-
ity against fluidizing action of proteins without
preventing the disruption of the liposomal architecture
by ultrasound.
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